{"id":"sequential-therapy-14-days","safety":{"commonSideEffects":[]},"_chembl":{"chemblId":"CHEMBL267665","moleculeType":"Small molecule","molecularWeight":"285.30"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This appears to be a standardized clinical protocol rather than a single drug entity. Sequential therapy typically involves administering different medications in a planned sequence to optimize therapeutic efficacy and minimize resistance or adverse effects. The 14-day duration suggests a short-term intensive treatment course, commonly used in infectious disease or certain cancer protocols.","oneSentence":"Sequential therapy 14 days is a treatment regimen combining multiple therapeutic agents administered in a defined sequence over a 14-day period.","_ai_confidence":"low"},"_scrapedAt":"2026-03-28T00:07:25.337Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[]},"trialDetails":[{"nctId":"NCT04267848","phase":"PHASE3","title":"Testing the Addition of a Type of Drug Called Immunotherapy to the Usual Chemotherapy Treatment for Non-small Cell Lung Cancer, an ALCHEMIST Treatment Trial (Chemo-IO [ACCIO])","status":"RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2020-06-16","conditions":"Lung Non-Small Cell Carcinoma, Lung Non-Small Cell Squamous Carcinoma, Lung Non-Squamous Non-Small Cell Carcinoma","enrollment":1210},{"nctId":"NCT02194738","phase":"NA","title":"Genetic Testing in Screening Patients With Stage IB-IIIA Non-small Cell Lung Cancer That Has Been or Will Be Removed by Surgery (The ALCHEMIST Screening Trial)","status":"ACTIVE_NOT_RECRUITING","sponsor":"National Cancer Institute (NCI)","startDate":"2014-09-26","conditions":"Stage IB Lung Non-Small Cell Carcinoma AJCC v7, Stage II Lung Non-Small Cell Cancer AJCC v7, Stage IIA Lung Cancer AJCC v8","enrollment":8300},{"nctId":"NCT05806931","phase":"PHASE2","title":"Sequential TAS-OX Alternating With TAS-IRI Plus Bevacizumab for Late-Line Metastatic Colorectal Cancer","status":"RECRUITING","sponsor":"Rutgers, The State University of New Jersey","startDate":"2023-05-17","conditions":"Colon Cancer, Rectal Cancer","enrollment":50},{"nctId":"NCT07194044","phase":"PHASE1","title":"Metastatic Ewing's Trial Testing Schedule Enhancement to Improve Outcomes","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2026-02","conditions":"Metastatic Ewing Sarcoma","enrollment":15},{"nctId":"NCT07410039","phase":"PHASE4","title":"Therapy in the Acute Phase of NMOSD: A Multicenter Prospective Real-World Study","status":"RECRUITING","sponsor":"Chinese PLA General Hospital","startDate":"2026-02-01","conditions":"Neuromyelitis Optica Spectrum Disorder Attack","enrollment":200},{"nctId":"NCT06087536","phase":"PHASE2","title":"A Clinical Trial to Assess the Safety and PK of OMN6 in HABP or VABP Caused by Acinetobacter Baumannii Complex","status":"RECRUITING","sponsor":"Omnix Medical Ltd","startDate":"2026-03","conditions":"Hospital-acquired Bacterial Pneumonia, Ventilator-associated Bacterial Pneumonia","enrollment":54},{"nctId":"NCT07453875","phase":"PHASE1","title":"LDRT Sequential NIPS Immunochemotherapy for Peritoneal Metastasis of Gastric and Colorectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Daping Hospital and the Research Institute of Surgery of the Third Military Medical University","startDate":"2026-02-09","conditions":"Peritoneal Metastasis of Gastric and Colorectal Cancer, LDRT","enrollment":9},{"nctId":"NCT07026474","phase":"PHASE3","title":"Re-Radiochemotherapy and Pembrolizumab vs. Immuno(Chemo)Therapy for Locoregionally Recurrent PD-L1 Positive (CPS≥1) HNSCC","status":"RECRUITING","sponsor":"Universität des Saarlandes","startDate":"2025-10-30","conditions":"Recurrent Head and Neck Squamous Cell Carcinoma","enrollment":214},{"nctId":"NCT04928807","phase":"PHASE3","title":"Short-Course Radiotherapy Followed by Neoadjuvant Chemotherapy and Camrelizumab in Locally Advanced Rectal Cancer (UNION)","status":"ACTIVE_NOT_RECRUITING","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2021-07-20","conditions":"Rectal Cancer","enrollment":231},{"nctId":"NCT07433387","phase":"PHASE1, PHASE2","title":"Exploratory Study of LP-98 for Injection in ART-Naive HIV-Infected Individuals","status":"RECRUITING","sponsor":"Shanxi Kangbao Biological Product Co., Ltd.","startDate":"2026-01-29","conditions":"HIV","enrollment":30},{"nctId":"NCT06156085","phase":"PHASE4","title":"Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy","status":"COMPLETED","sponsor":"Fu Jen Catholic University Hospital","startDate":"2023-11-14","conditions":"Helicobacter Pylori Infection","enrollment":337},{"nctId":"NCT06325748","phase":"PHASE1","title":"SENTI-202: Off-the-shelf Logic Gated CAR NK Cell Therapy in Adults With CD33 and/or FLT3 Blood Cancers Including AML/MDS","status":"ACTIVE_NOT_RECRUITING","sponsor":"Senti Biosciences","startDate":"2024-04-22","conditions":"AML/MDS, CD33 Expressing Hematological Malignancies, FLT3 Expressing Hematological Malignancies","enrollment":21},{"nctId":"NCT06685809","phase":"PHASE1","title":"A Phase 1 Study of FZ008-145 in Healthy Subjects.","status":"RECRUITING","sponsor":"Guangzhou Fermion Technology Co., LTD","startDate":"2024-11-25","conditions":"Healthy","enrollment":190},{"nctId":"NCT07275905","phase":"PHASE1","title":"Bacteriophages for Adults With Cystic Fibrosis and Chronic Achromobacter Lung Infection","status":"NOT_YET_RECRUITING","sponsor":"Ghady Haidar","startDate":"2026-03","conditions":"Cystic Fibrosis (CF), Achromobacter Infection","enrollment":12},{"nctId":"NCT07025226","phase":"EARLY_PHASE1","title":"Sequential Treatments or Combinations Including Dasatinib, Quercetin, Fisetin and/or Temozolomide for the Treatment of Previously Treated Glioma With Residual Disease","status":"RECRUITING","sponsor":"Mayo Clinic","startDate":"2025-08-12","conditions":"Glioma","enrollment":10},{"nctId":"NCT03505905","phase":"PHASE1, PHASE2","title":"A Neurosteroid Intervention for Menopausal and Perimenopausal Depression","status":"COMPLETED","sponsor":"University of Texas Southwestern Medical Center","startDate":"2018-09-01","conditions":"Major Depressive Disorder, Menopause, Perimenopause","enrollment":73},{"nctId":"NCT05281510","phase":"PHASE2","title":"Study of VRC07-523LS, CAP256V2LS, and Vesatolimod, in Early Antiretroviral-treated HIV-1 Clade C-infected Women","status":"COMPLETED","sponsor":"Gilead Sciences","startDate":"2022-06-09","conditions":"HIV-1-infection","enrollment":20},{"nctId":"NCT06429449","phase":"PHASE1","title":"Mitoxantrone for Venetoclax Resistant Acute Myeloid Leukemia","status":"RECRUITING","sponsor":"University of Colorado, Denver","startDate":"2024-07-21","conditions":"Leukemia, Myeloid Leukemia, Monocytic Leukemia","enrollment":30},{"nctId":"NCT07313241","phase":"PHASE2","title":"Phase II Trial of PSA Response-based Androgen Deprivation Therapy and Nodal Coverage for Prostate Cancer Early Salvage Radiotherapy (RANGER)","status":"RECRUITING","sponsor":"University of Texas Southwestern Medical Center","startDate":"2025-11-14","conditions":"Prostate Cancer","enrollment":68},{"nctId":"NCT07141264","phase":"PHASE2","title":"Adebrelimab Combine With Etoposide Capsules in ES-SCLC Maintenance Therapy","status":"RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2025-08-25","conditions":"SCLC,Extensive Stage","enrollment":32},{"nctId":"NCT04432571","phase":"NA","title":"ADAPT for Adolescents Adolescents","status":"ACTIVE_NOT_RECRUITING","sponsor":"Washington University School of Medicine","startDate":"2021-04-06","conditions":"HIV/AIDS","enrollment":880},{"nctId":"NCT06903156","phase":"PHASE2","title":"Efficacy and Safety of Different Dosages of Mexidol® in Patients With Primary Open-angle Glaucoma (POAG)","status":"COMPLETED","sponsor":"Pharmasoft","startDate":"2021-11-15","conditions":"Primary Open-Angle Glaucoma (POAG)","enrollment":102},{"nctId":"NCT06437639","phase":"PHASE4","title":"MEXIDOL® Sequential Therapy of Patients With Primary Open-angle Glaucoma (POAG)","status":"COMPLETED","sponsor":"Pharmasoft","startDate":"2023-09-15","conditions":"Primary Open-Angle Glaucoma (POAG)","enrollment":80},{"nctId":"NCT06409390","phase":"PHASE2","title":"Sequential Therapies Modeled on Evolutionary Dynamics for Breast Cancer","status":"RECRUITING","sponsor":"H. Lee Moffitt Cancer Center and Research Institute","startDate":"2024-08-14","conditions":"Metastatic Breast Cancer","enrollment":15},{"nctId":"NCT06928662","phase":"PHASE1, PHASE2","title":"Chemotherapy (Decitabine in Combination With FLAG-Ida) and Total-Body Irradiation Followed by Donor Stem Cell Transplant for the Treatment of Adults With Myeloid Malignancies at High Risk of Relapse","status":"RECRUITING","sponsor":"Fred Hutchinson Cancer Center","startDate":"2025-09-23","conditions":"Acute Myeloid Leukemia, Acute Undifferentiated Leukemia, Mixed Phenotype Acute Leukemia","enrollment":36},{"nctId":"NCT06834490","phase":"PHASE3","title":"Safety and Efficacy of Sequential Therapy With Mexidol® in Patients With Chronic Cerebral Ischemia","status":"COMPLETED","sponsor":"Pharmasoft","startDate":"2019-11-05","conditions":"Chronic Cerebral Ischemia","enrollment":318},{"nctId":"NCT03813784","phase":"PHASE3","title":"A Clinical Study To Evaluate Camrelizumab (SHR-1210) Plus Capecitabine and Oxaliplatin Followed by Sequential Treatment With Camrelizumab Plus Apatinib Mesylate in Advanced or Metastatic Gastric Cancer (GC) or Gastroesophageal Junction Cancer (GEJ) Without Prior Systemic Therapy","status":"COMPLETED","sponsor":"Jiangsu HengRui Medicine Co., Ltd.","startDate":"2019-03-07","conditions":"Gastric Cancer, GastroEsophageal Cancer","enrollment":885},{"nctId":"NCT04332848","phase":"PHASE4","title":"Susceptibility Testing Guided Versus Empirical Therapy for Refractory H. Pylori Infection","status":"RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2020-07-28","conditions":"Helicobacter Pylori Infection","enrollment":360},{"nctId":"NCT07122180","phase":"","title":"Post-Market Clinical Follow-Up of the CT3 Series Continuous Glucose Monitoring System: A 14-Day Observational Study Assessing Accuracy, Safety, and Glucose Control in Patients With Type 1 and Type 2 Diabetes Mellitus","status":"ENROLLING_BY_INVITATION","sponsor":"MDCECRO LLC","startDate":"2025-06-04","conditions":"Diabetes Mellitus","enrollment":72},{"nctId":"NCT07130253","phase":"NA","title":"Efficacy of Vonoprazan-based Rescue Therapy for H. Pylori Eradication","status":"NOT_YET_RECRUITING","sponsor":"National Taiwan University Hospital","startDate":"2025-08-18","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":220},{"nctId":"NCT07121088","phase":"PHASE4","title":"Traditional Chinese Medicine Intervention for Ischemic Cerebrovascular Disease and Diabetes Mellitus: An Efficacy Comparative Study","status":"NOT_YET_RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2025-08-31","conditions":"Ischemic Cerebral Infarction, Diabetes Mellitus","enrollment":3666},{"nctId":"NCT06930105","phase":"PHASE2","title":"Impact of Low-intensity Chemotherapy Combined With Short-course Blinatumomab on Allo-HSCT in Adults With Ph- B-ALL","status":"NOT_YET_RECRUITING","sponsor":"Xianmin Song, MD","startDate":"2025-09-01","conditions":"Acute Lymphoid Leukemia (ALL)","enrollment":45},{"nctId":"NCT05781399","phase":"PHASE1, PHASE2","title":"First-in-Human, Multiple Part Clinical Study of JNT-517 in Healthy Participants and in Participants With Phenylketonuria","status":"ACTIVE_NOT_RECRUITING","sponsor":"Otsuka Pharmaceutical Development & Commercialization, Inc.","startDate":"2022-10-31","conditions":"Phenylketonuria","enrollment":135},{"nctId":"NCT07088523","phase":"PHASE4","title":"Traditional Chinese Medicine Intervention for Ischemic Cardiovascular Disease Comorbid With Diabetes Mellitus: An Efficacy Comparative Study","status":"NOT_YET_RECRUITING","sponsor":"Guangzhou University of Traditional Chinese Medicine","startDate":"2025-07-31","conditions":"Diabete Mellitus, Ischemic Cardiovascular Disease","enrollment":4205},{"nctId":"NCT07064278","phase":"NA","title":"Combined Diagnostic Approach for Refractory Mycoplasma Pneumonia in Children","status":"COMPLETED","sponsor":"Children's Hospital of Hebei Province","startDate":"2022-12-01","conditions":"Refractory Mycoplasma Pneumoniae Pneumonia","enrollment":260},{"nctId":"NCT06520345","phase":"PHASE3","title":"The Study of 177Lu-TLX591 Plus SOC Versus SOC Alone in Patients With mCRPC (ProstACT Global)","status":"RECRUITING","sponsor":"Telix Pharmaceuticals (Innovations) Pty Limited","startDate":"2024-07-26","conditions":"Metastatic Castration-resistant Prostate Cancer","enrollment":430},{"nctId":"NCT07019272","phase":"","title":"Neratinib in Extended Adjuvant Treatment for HER2+ Early Breast Cancer With pCR But High-Risk Features: A Hebei Multi-Center Real-World Study","status":"NOT_YET_RECRUITING","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2025-06-30","conditions":"HER2-positive Breast Cancer","enrollment":170},{"nctId":"NCT04952480","phase":"PHASE2","title":"Dose-escalated Adaptive Radiotherapy of Thoracic Disease for Small Cell Lung Cancer","status":"RECRUITING","sponsor":"AHS Cancer Control Alberta","startDate":"2022-06-13","conditions":"Small Cell Lung Cancer","enrollment":31},{"nctId":"NCT02711202","phase":"NA","title":"Sequential Targeting of Cluster of Differentiation 52 (CD52) and Tumor Necrosis Factor (TNF) Allows Early Minimization Therapy in Kidney Transplantation","status":"COMPLETED","sponsor":"Institute for Clinical and Experimental Medicine","startDate":"2007-01","conditions":"Kidney Transplantation","enrollment":20},{"nctId":"NCT06929962","phase":"PHASE4","title":"VA Dual Sequential Therapy","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-04-24","conditions":"Helicobacter Pylori Infection","enrollment":600},{"nctId":"NCT05363293","phase":"PHASE1, PHASE2","title":"Multiple Ascending Dose Safety, Tolerability, PK Study of AL001 in Alzheimer's Disease Patients & Healthy Adult Subjects","status":"COMPLETED","sponsor":"Alzamend Neuro, Inc.","startDate":"2022-05-04","conditions":"Alzheimer's Disease, Healthy Non-elderly and Elderly Adults","enrollment":65},{"nctId":"NCT06422858","phase":"PHASE2","title":"Sequential Tegafur-gimeracil-oteracil Potassium Capsule (s-1) and Serplulimab Following Concurrent Chemoradiotherapy for Esophageal Squamous Cell Carcinoma","status":"RECRUITING","sponsor":"Zhejiang Cancer Hospital","startDate":"2024-05-20","conditions":"Locally Advanced Inoperable Esophageal Squamous Cell Carcinoma","enrollment":37},{"nctId":"NCT06911684","phase":"PHASE2","title":"Radiotherapy Plus Iparomlimab and Tuvonralimab (QL1706), Regorafenib, and CAPOX as Neoadjuvant Therapy for pMMR/MSS LARC.","status":"RECRUITING","sponsor":"Sun Yat-sen University","startDate":"2025-04-30","conditions":"Rectal Cancer Patients","enrollment":88},{"nctId":"NCT05804669","phase":"PHASE1, PHASE2","title":"A Study to Evaluate the Safety and PK of CRN04894 for the Treatment of Cushing's Syndrome","status":"RECRUITING","sponsor":"Crinetics Pharmaceuticals Inc.","startDate":"2023-10-12","conditions":"Cushing Syndrome, Cushing Disease, Ectopic ACTH Syndrome","enrollment":18},{"nctId":"NCT06718543","phase":"PHASE2","title":"Neoadjuvant Short-Course Radiotherapy With or Without Chemotherapy and AK112 in Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"fan li","startDate":"2025-02-10","conditions":"Rectal Cancer","enrollment":100},{"nctId":"NCT05567289","phase":"","title":"Precision Medicine for Stem Cell Transplantation","status":"RECRUITING","sponsor":"University of Manchester","startDate":"2023-06-06","conditions":"Haematopoietic Stem Cell Transplantation","enrollment":300},{"nctId":"NCT06246344","phase":"","title":"Adaptive Boost Radiotherapy to Primary Lesions and Positive Nodes in the Neoadjuvant Treatment of Locally Advanced Rectal Cancer","status":"RECRUITING","sponsor":"Shandong Cancer Hospital and Institute","startDate":"2023-12-01","conditions":"Rectal Cancer","enrollment":128},{"nctId":"NCT04165330","phase":"PHASE1, PHASE2","title":"Evaluation of AL3818 in Combination With Nivolumab in Solid Tumors","status":"ACTIVE_NOT_RECRUITING","sponsor":"Sarcoma Oncology Research Center, LLC","startDate":"2019-10-17","conditions":"Solid Tumor, Adult, Soft Tissue Sarcoma, Non Small Cell Lung Cancer","enrollment":56},{"nctId":"NCT06601452","phase":"EARLY_PHASE1","title":"Clinical Trial of Anovulatory Infertility","status":"ENROLLING_BY_INVITATION","sponsor":"Affiliated Hospital of Nanjing University of Chinese Medicine","startDate":"2024-09-30","conditions":"Polycystic Ovary Syndrome, Diminished Ovarian Reserve, Ovulation Disorder","enrollment":650},{"nctId":"NCT06816615","phase":"NA","title":"Diagnosis and Percutaneous Treatment of Biliary Tract Diseases","status":"RECRUITING","sponsor":"IRCCS Azienda Ospedaliero-Universitaria di Bologna","startDate":"2022-10-14","conditions":"Gallstone, Biliary Stricture, Biliary Diseases","enrollment":24},{"nctId":"NCT02794571","phase":"PHASE1","title":"Safety and Pharmacokinetics (PK) of Escalating Doses of Tiragolumab as a Single Agent and in Combination With Atezolizumab and/or Other Anti-Cancer Therapies in Locally Advanced or Metastatic Tumors","status":"COMPLETED","sponsor":"Genentech, Inc.","startDate":"2016-05-23","conditions":"Advanced/Metastatic Tumors","enrollment":518},{"nctId":"NCT00754065","phase":"PHASE3","title":"To Compare SH T00658ID Over Ortho Tri-Cyclen Lo (US/Canada)","status":"COMPLETED","sponsor":"Bayer","startDate":"2008-09-08","conditions":"Contraception","enrollment":409},{"nctId":"NCT05475431","phase":"","title":"Real-world Treatment of H. Pylori Eradication in Patients with Comorbidity","status":"COMPLETED","sponsor":"National Cheng-Kung University Hospital","startDate":"2020-05-06","conditions":"Helicobacter Pylori Infection, Comorbidities and Coexisting Conditions, Real-world Outcome","enrollment":1053},{"nctId":"NCT01811992","phase":"PHASE1","title":"Combined Cytotoxic and Immune-Stimulatory Therapy for Glioma","status":"COMPLETED","sponsor":"University of Michigan Rogel Cancer Center","startDate":"2014-04","conditions":"Malignant Glioma, Glioblastoma Multiforme","enrollment":19},{"nctId":"NCT04246684","phase":"PHASE3","title":"Short RT Versus RCT,Followed by Chemo.and Organ Preservation for Interm and High-risk Rectal Cancer Patients","status":"ACTIVE_NOT_RECRUITING","sponsor":"Prof. Dr. med. Claus Rödel","startDate":"2020-11-05","conditions":"Rectal Cancer Stage III","enrollment":702},{"nctId":"NCT05086627","phase":"PHASE2","title":"Short-course Radiotherapy Followed by Tislelizumab + CapeOX in the Treatment for Locally Advanced Rectal Cancer","status":"COMPLETED","sponsor":"Hebei Medical University Fourth Hospital","startDate":"2021-09-01","conditions":"Locally Advanced Rectal Cancer","enrollment":118},{"nctId":"NCT06475209","phase":"PHASE2","title":"Adebrelimab + Apatinib in SCLC Maintenance Therapy","status":"RECRUITING","sponsor":"Tang-Du Hospital","startDate":"2024-06-20","conditions":"SCLC","enrollment":60},{"nctId":"NCT04092673","phase":"PHASE1, PHASE2","title":"Study of eFT226 in Subjects With Selected Advanced Solid Tumor Malignancies","status":"RECRUITING","sponsor":"Effector Therapeutics","startDate":"2019-10-25","conditions":"Solid Tumor, Adult","enrollment":30},{"nctId":"NCT00346632","phase":"PHASE1","title":"An Ascending Dose Study of KW-2449 in Acute Leukemias, Myelodysplastic Syndromes, and Chronic Myelogenous Leukemia","status":"TERMINATED","sponsor":"Kyowa Kirin, Inc.","startDate":"2006-06","conditions":"Acute Myelogenous Leukemia, Acute Lymphoblastic Leukemia, Myelodysplastic Syndromes","enrollment":37},{"nctId":"NCT06410963","phase":"NA","title":"ReActivate: Physiotherapist Led Intervention for Adolescents With Pain and Psychological Distress.","status":"RECRUITING","sponsor":"Örebro University, Sweden","startDate":"2024-06-01","conditions":"Chronic Pain, Emotional Distress","enrollment":35},{"nctId":"NCT06379620","phase":"PHASE1","title":"Pilot Open Label Use of the Hi-OXSR for the Treatment of Post COVID-19 Cognitive Dysfunction","status":"COMPLETED","sponsor":"University Health Network, Toronto","startDate":"2022-11-29","conditions":"Post COVID-19 Condition","enrollment":37},{"nctId":"NCT04124601","phase":"PHASE2","title":"Neoadjuvant Chemoradiotherapy With Sequential Ipilimumab and Nivolumab in Rectal Cancer","status":"COMPLETED","sponsor":"Johannes Laengle, MD, PhD","startDate":"2020-06-01","conditions":"Rectal Cancer","enrollment":80},{"nctId":"NCT02085148","phase":"PHASE1","title":"A Phase I Dose Finding Study in Children With Solid Tumors Recurrent or Refractory to Standard Therapy","status":"COMPLETED","sponsor":"Bayer","startDate":"2014-04-11","conditions":"Pediatric Oncology","enrollment":62},{"nctId":"NCT06176781","phase":"PHASE3","title":"The Efficacy and Safety of Edaravone Dexborneol Sequential Therapy in the Treatment of Patients With AIS","status":"UNKNOWN","sponsor":"Simcere Pharmaceutical Co., Ltd","startDate":"2023-12-28","conditions":"Subjects With Acute Ischemic Stroke","enrollment":880},{"nctId":"NCT05549115","phase":"NA","title":"Susceptibility-Guided Sequential Therapy for Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Liaocheng People's Hospital","startDate":"2022-09-20","conditions":"Helicobacter Pylori Infection","enrollment":500},{"nctId":"NCT02584478","phase":"PHASE3","title":"Phase 1/2a/3 Evaluation of Adding AL3818 to Standard Platinum-Based Chemotherapy in Subjects With Recurrent or Metastatic Endometrial, Ovarian, Fallopian, Primary Peritoneal or Cervical Carcinoma (AL3818-US-002)","status":"UNKNOWN","sponsor":"Advenchen Laboratories, LLC","startDate":"2015-12","conditions":"Endometrial Carcinoma, Ovarian Carcinoma, Fallopian Tube Carcinoma","enrollment":294},{"nctId":"NCT03305419","phase":"PHASE1","title":"A Safety and Pharmacokinetic (PK) Study of GSK2982772 in Healthy Subjects","status":"COMPLETED","sponsor":"GlaxoSmithKline","startDate":"2017-10-11","conditions":"Autoimmune Diseases","enrollment":62},{"nctId":"NCT01484093","phase":"PHASE1, PHASE2","title":"Sequential Chemo-Radioimmunotherapy Followed by Autologous Transplantation for Patients With Untreated Advanced Stage Mantle Cell Lymphoma","status":"COMPLETED","sponsor":"Memorial Sloan Kettering Cancer Center","startDate":"2011-11-29","conditions":"Mantle Cell Lymphoma","enrollment":96},{"nctId":"NCT04987671","phase":"PHASE1, PHASE2","title":"Pharmacokinetic and Pharmacodynamic Study of AMX0035 in Patients With ALS","status":"UNKNOWN","sponsor":"Amylyx Pharmaceuticals Inc.","startDate":"2021-08-05","conditions":"ALS","enrollment":14},{"nctId":"NCT05947604","phase":"PHASE1","title":"DDI Study of Single Oral Dose of Acoziborole With Sequential Co-administration of Midazolam and Dextromethorphan","status":"COMPLETED","sponsor":"Drugs for Neglected Diseases","startDate":"2023-02-09","conditions":"Trypanosomiasis, African","enrollment":20},{"nctId":"NCT04447053","phase":"PHASE4","title":"Sequential Belimumab and T-cell Based Therapy in SLE","status":"UNKNOWN","sponsor":"National University Hospital, Singapore","startDate":"2021-11-08","conditions":"Systemic Lupus Erythematosus","enrollment":80},{"nctId":"NCT05479240","phase":"PHASE2","title":"Neoadjuvant Chemoradiotherapy Combined With Tislelizumab in the Treatment of Locally Advanced Rectal Cancer","status":"NOT_YET_RECRUITING","sponsor":"Fujian Cancer Hospital","startDate":"2023-09-01","conditions":"Immunotherapy","enrollment":94},{"nctId":"NCT02373280","phase":"NA","title":"The Efficacy of the 7 Days Tailored Therapy as the 1st Eradication of H. Pylori Infection","status":"UNKNOWN","sponsor":"Seoul National University Bundang Hospital","startDate":"2014-08","conditions":"Helicobacter Infection","enrollment":600},{"nctId":"NCT05813015","phase":"PHASE3","title":"Study of Comparing of With and Without Sequential Therapy of S-1","status":"RECRUITING","sponsor":"Zhejiang University","startDate":"2023-01-28","conditions":"Locally Advanced Gastric Adenocarcinoma, Chemotherapy Effect","enrollment":70},{"nctId":"NCT05772377","phase":"PHASE2","title":"Anlotinib Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Cancer","status":"UNKNOWN","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2023-07-01","conditions":"To Evaluate the Efficacy and Safety of Anlotinib Combined With Concurrent Chemoradiotherapy in the Treatment of Locally Advanced Cervical Cancer","enrollment":36},{"nctId":"NCT04297748","phase":"PHASE1, PHASE2","title":"Bioimaging Study of 89Zr-M7824 in NSCLC","status":"TERMINATED","sponsor":"Olivia Newton-John Cancer Research Institute","startDate":"2020-06-01","conditions":"Non-Small Cell Lung Cancer","enrollment":5},{"nctId":"NCT05679050","phase":"PHASE2","title":"Phase II Study on Sequential AG and FOLFIRINOX as Neoadjuvant Therapy in Patients With Resectable Pancreatic Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2022-10-01","conditions":"Resectable Pancreatic Cancer","enrollment":30},{"nctId":"NCT05021094","phase":"PHASE4","title":"Clinical Observation on Kuntai Capsule in Treating Early-onset Ovarian Hypofunction","status":"UNKNOWN","sponsor":"Affiliated Hospital of Nantong University","startDate":"2021-10-22","conditions":"Primary Ovarian Insufficiency","enrollment":120},{"nctId":"NCT01516593","phase":"PHASE2","title":"Short Term Intensified Chemo-immunotherapy in HIV-positive Patients With Burkitt Lymphoma","status":"COMPLETED","sponsor":"Andres J. M. Ferreri","startDate":"2011-11","conditions":"HIV, Burkitt's Lymphoma","enrollment":19},{"nctId":"NCT05449028","phase":"NA","title":"Helicobacter Pylori Eradication Therapy in Portugal","status":"UNKNOWN","sponsor":"Unidade Local de Saúde de Coimbra, EPE","startDate":"2022-05-01","conditions":"Helicobacter Pylori, Gut Microbiota, Immunology","enrollment":230},{"nctId":"NCT04138875","phase":"PHASE2","title":"A Risk Stratified Sequential Treatment With Rituximab, Brentuximab Vedotin and Bendamustine (RBvB)","status":"WITHDRAWN","sponsor":"Yale University","startDate":"2022-01","conditions":"PTLD, Lymphoid Tumor, Hematopoietic/Lymphoid Cancer","enrollment":""},{"nctId":"NCT02663271","phase":"PHASE2","title":"TTFields and Pulsed Bevacizumab for Recurrent Glioblastoma","status":"TERMINATED","sponsor":"University of Florida","startDate":"2016-12-19","conditions":"Glioblastoma Multiforme, Glioblastoma, Malignant Glioma","enrollment":10},{"nctId":"NCT03148366","phase":"PHASE3","title":"Comparison of the Levofloxacin Sequential Therapy and Quadruple Therapy in Second Line Treatment for HP","status":"COMPLETED","sponsor":"National Taiwan University Hospital","startDate":"2015-02","conditions":"Helicobacter","enrollment":560},{"nctId":"NCT04325763","phase":"PHASE3","title":"A Study of TQB2450 in Subjects With Stage III Non-Small Cell Lung Cancer(NSCLC)","status":"UNKNOWN","sponsor":"Chia Tai Tianqing Pharmaceutical Group Co., Ltd.","startDate":"2020-05-27","conditions":"Stage III Non-small-cell Lung Cancer","enrollment":315},{"nctId":"NCT05255523","phase":"PHASE2","title":"Pyrotinib Plus Trastuzumab After First-line TH (P) Treatment With HER-2 Positive Breast Cancer","status":"UNKNOWN","sponsor":"Fujian Medical University Union Hospital","startDate":"2022-02-20","conditions":"Advanced Breast Cancer","enrollment":60},{"nctId":"NCT03035630","phase":"PHASE2","title":"Sunitinib Followed by Avelumab or the Reverse for Metastatic Renal Cell Carcinoma","status":"WITHDRAWN","sponsor":"Guru Sonpavde","startDate":"2017-05-23","conditions":"Clear-cell Renal Cell Carcinoma, RCC, Kidney Cancer","enrollment":""},{"nctId":"NCT03840616","phase":"PHASE3","title":"Study of Oral Oteseconazole (VT-1161) for Acute Yeast Infections in Patients With Recurrent Yeast Infections","status":"COMPLETED","sponsor":"Mycovia Pharmaceuticals Inc.","startDate":"2019-03-13","conditions":"Recurrent Vulvovaginal Candidiasis","enrollment":219},{"nctId":"NCT03580278","phase":"PHASE1","title":"A Study to Investigate the Safety, Tolerability, Pharmacokinetic, and Efficacy of ABY-035/AFO2","status":"COMPLETED","sponsor":"Affibody","startDate":"2019-11-13","conditions":"Psoriasis","enrollment":33},{"nctId":"NCT04842825","phase":"PHASE3","title":"Sequential Therapy of TCM Herbs to Improve the Success Rate of IVF-ET in Diminished Ovarian Reserve Patients","status":"UNKNOWN","sponsor":"Peking University Third Hospital","startDate":"2021-04-15","conditions":"Infertility, Female","enrollment":200},{"nctId":"NCT04882033","phase":"PHASE1","title":"Concurrent Chemoradiotherapy Combination With Anlotinib for Limited-stage Small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Tianjin Medical University Cancer Institute and Hospital","startDate":"2021-05-07","conditions":"Small Cell Lung Cancer Limited Stage","enrollment":9},{"nctId":"NCT00365417","phase":"PHASE2","title":"Therapy With Bevacizumab (BEV), Doxorubicin, and Cyclophosphamide Followed by BEV, Docetaxel, and Capecitabine Before Surgery Followed by BEV Alone After Surgery for Women With Locally Advanced Breast Cancer","status":"COMPLETED","sponsor":"NSABP Foundation Inc","startDate":"2006-08","conditions":"Breast Cancer","enrollment":45},{"nctId":"NCT01181128","phase":"PHASE3","title":"Study to Evaluate the Safety, Pharmacokinetics and Efficacy of Recombinant Factor VIII Fc Fusion Protein (rFVIIIFc) in Previously Treated Subjects With Severe Hemophilia A","status":"COMPLETED","sponsor":"Bioverativ Therapeutics Inc.","startDate":"2010-11","conditions":"Severe Hemophilia A","enrollment":165},{"nctId":"NCT03108027","phase":"PHASE2","title":"Assess Bronchodilator Effect QVM149 Dosed Either in the Morning or Evening Compared to Placebo in Patients With Asthma","status":"COMPLETED","sponsor":"Novartis Pharmaceuticals","startDate":"2017-06-26","conditions":"Asthma","enrollment":38},{"nctId":"NCT01697293","phase":"PHASE1, PHASE2","title":"PTX-200, Paclitaxel, Doxorubicin Hydrochloride, and Cyclophosphamide in Treating Patients With Stage IIB-IV Breast Cancer","status":"TERMINATED","sponsor":"Prescient Therapeutics, Ltd.","startDate":"2012-01","conditions":"Breast Adenocarcinoma, Estrogen Receptor Positive, HER2/Neu Negative","enrollment":34},{"nctId":"NCT04445948","phase":"PHASE4","title":"Lactoferrin in Helicobacter Pylori Eradication Either With Standard Triple Therapy or Sequential Therapy","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2019-11-30","conditions":"Helicobacter Pylori Infection","enrollment":400},{"nctId":"NCT03836729","phase":"PHASE1","title":"Study to Evaluate the Effect of GSK3640254 on the Pharmacokinetics of Tenofovir Alafenamide/Emtricitabine","status":"COMPLETED","sponsor":"ViiV Healthcare","startDate":"2019-02-11","conditions":"HIV Infections","enrollment":16},{"nctId":"NCT04314297","phase":"PHASE2","title":"Anlotinib In Combination With Durvalumab As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study","status":"UNKNOWN","sponsor":"Union Hospital, Tongji Medical College, Huazhong University of Science and Technology","startDate":"2020-04","conditions":"Anlotinib, Durvalumab, Small Cell Lung Cancer","enrollment":33},{"nctId":"NCT04313660","phase":"PHASE2","title":"Anlotinib In Combination With PD-1/L1 Inhibitor As Sequential Therapy of Thoracic Radiotherapy After Induction Chemotherapy For Extensive-Stage Small Cell Lung Cancer:A Single Arm Study","status":"UNKNOWN","sponsor":"Xiaorong Dong","startDate":"2020-04","conditions":"NSCLC, Anlotinib, PD-1/L1 Inhibitor","enrollment":33},{"nctId":"NCT04132479","phase":"PHASE4","title":"The Epidemiology and Optimal Treatment of Helicobacter Pylori in Myanmar","status":"COMPLETED","sponsor":"Kirby Institute","startDate":"2018-01-01","conditions":"Helicobacter Pylori Infection","enrollment":313},{"nctId":"NCT04111913","phase":"PHASE2","title":"A Study of Sequential Anlotinib Followed by EP Regimen Plus Concurrent Radiotherapy for Unresectable Stage III Non-small Cell Lung Cancer","status":"UNKNOWN","sponsor":"Nanfang Hospital, Southern Medical University","startDate":"2019-10-01","conditions":"Unresectable Stage III Non-small Cell Lung Cancer","enrollment":100}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":1,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":[],"phase":"marketed","status":"active","brandName":"Sequential therapy 14 days","genericName":"Sequential therapy 14 days","companyName":"Incheon St.Mary's Hospital","companyId":"incheon-st-mary-s-hospital","modality":"Small molecule","firstApprovalDate":"","aiSummary":"","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"partial","dataCompleteness":{"mechanism":true,"indications":false,"safety":false,"trials":true,"score":2}}